Dan Xu1, Fuling Zhou2, Wenbo Sun1, Liangjun Chen3, Lan Lan1, Huan Li1, Feng Xiao1, Ying Li1, Vijaya B Kolachalama4, Yirong Li3, Xinghuan Wang5, Haibo Xu1. 1. Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. 2. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. 3. Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. 4. Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. 5. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and has the ability to damage multiple organs. However, information on serum SARS-CoV-2 nucleic acid (RNAemia) in patients affected by coronavirus disease 2019 (COVID-19) is limited. METHODS: Patients who were admitted to Zhongnan Hospital of Wuhan University with laboratory-confirmed COVID-19 were tested for SARS-COV-2 RNA in serum from 28 January 2020 to 9 February 2020. Demographic data, laboratory and radiological findings, comorbidities, and outcomes data were collected and analyzed. RESULTS: Eighty-five patients were included in the analysis. The viral load of throat swabs was significantly higher than of serum samples. The highest detection of SARS-CoV-2 RNA in serum samples was between 11 and 15 days after symptom onset. Analysis to compare patients with and without RNAemia provided evidence that computed tomography and some laboratory biomarkers (total protein, blood urea nitrogen, lactate dehydrogenase, hypersensitive troponin I, and D-dimer) were abnormal and that the extent of these abnormalities was generally higher in patients with RNAemia than in patients without RNAemia. Organ damage (respiratory failure, cardiac damage, renal damage, and coagulopathy) was more common in patients with RNAemia than in patients without RNAemia. Patients with vs without RNAemia had shorter durations from serum testing SARS-CoV-2 RNA. The mortality rate was higher among patients with vs without RNAemia. CONCLUSIONS: In this study, we provide evidence to support that SARS-CoV-2 may have an important role in multiple organ damage. Our evidence suggests that RNAemia has a significant association with higher risk of in-hospital mortality.
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and has the ability to damage multiple organs. However, information on serum SARS-CoV-2 nucleic acid (RNAemia) in patients affected by coronavirus disease 2019 (COVID-19) is limited. METHODS:Patients who were admitted to Zhongnan Hospital of Wuhan University with laboratory-confirmed COVID-19 were tested for SARS-COV-2 RNA in serum from 28 January 2020 to 9 February 2020. Demographic data, laboratory and radiological findings, comorbidities, and outcomes data were collected and analyzed. RESULTS: Eighty-five patients were included in the analysis. The viral load of throat swabs was significantly higher than of serum samples. The highest detection of SARS-CoV-2 RNA in serum samples was between 11 and 15 days after symptom onset. Analysis to compare patients with and without RNAemia provided evidence that computed tomography and some laboratory biomarkers (total protein, blood urea nitrogen, lactate dehydrogenase, hypersensitive troponin I, and D-dimer) were abnormal and that the extent of these abnormalities was generally higher in patients with RNAemia than in patients without RNAemia. Organ damage (respiratory failure, cardiac damage, renal damage, and coagulopathy) was more common in patients with RNAemia than in patients without RNAemia. Patients with vs without RNAemia had shorter durations from serum testing SARS-CoV-2 RNA. The mortality rate was higher among patients with vs without RNAemia. CONCLUSIONS: In this study, we provide evidence to support that SARS-CoV-2 may have an important role in multiple organ damage. Our evidence suggests that RNAemia has a significant association with higher risk of in-hospital mortality.
Authors: Tobias Schlesinger; Benedikt Weißbrich; Florian Wedekink; Quirin Notz; Johannes Herrmann; Manuel Krone; Magdalena Sitter; Benedikt Schmid; Markus Kredel; Jan Stumpner; Lars Dölken; Jörg Wischhusen; Peter Kranke; Patrick Meybohm; Christopher Lotz Journal: PLoS One Date: 2020-11-24 Impact factor: 3.240
Authors: Jana L Jacobs; William Bain; Asma Naqvi; Brittany Staines; Priscila M S Castanha; Haopu Yang; Valerie F Boltz; Simon Barratt-Boyes; Ernesto T A Marques; Stephanie L Mitchell; Barbara Methé; Tolani F Olonisakin; Ghady Haidar; Thomas W Burke; Elizabeth Petzold; Thomas Denny; Chris W Woods; Bryan J McVerry; Janet S Lee; Simon C Watkins; Claudette M St Croix; Alison Morris; Mary F Kearney; Mark S Ladinsky; Pamela J Bjorkman; Georgios D Kitsios; John W Mellors Journal: Clin Infect Dis Date: 2022-05-03 Impact factor: 20.999
Authors: Nikhil Ram-Mohan; David Kim; Elizabeth J Zudock; Marjan M Hashemi; Kristel C Tjandra; Angela J Rogers; Catherine A Blish; Kari C Nadeau; Jennifer A Newberry; James V Quinn; Ruth O'Hara; Euan Ashley; Hien Nguyen; Lingxia Jiang; Paul Hung; Andra L Blomkalns; Samuel Yang Journal: medRxiv Date: 2020-12-22